Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $40.00 at BTIG Research

Cullinan Therapeutics (NASDAQ:CGEM) had its price objective upped by stock analysts at BTIG Research from $39.00 to $40.00 in a research note issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 92.83% from the company’s current price.

Several other analysts have also issued reports on CGEM. Wedbush upped their price target on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Cullinan Therapeutics in a research report on Monday, August 17th. Finally, TD Cowen raised Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Cullinan Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Cullinan Therapeutics Trading Up 0.7%

CGEM stock traded up $0.15 during trading on Monday, reaching $20.74. 643,455 shares of the stock were exchanged, compared to its average volume of 859,782. Cullinan Therapeutics has a twelve month low of $5.68 and a twelve month high of $23.19. The firm’s 50 day moving average is $19.46 and its 200 day moving average is $16.43. The firm has a market cap of $1.34 billion, a P/E ratio of -6.68 and a beta of 0.02.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). As a group, analysts predict that Cullinan Therapeutics will post -3.08 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total value of $172,560.00. Following the completion of the transaction, the insider owned 158,844 shares of the company’s stock, valued at approximately $3,426,265.08. This trade represents a 4.79% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 46,000 shares of company stock worth $922,920. 8.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Cullinan Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd bought a new stake in shares of Cullinan Therapeutics in the 1st quarter worth about $163,000. Jane Street Group LLC increased its stake in Cullinan Therapeutics by 145.9% in the first quarter. Jane Street Group LLC now owns 34,396 shares of the company’s stock worth $260,000 after purchasing an additional 109,413 shares during the period. Acadian Asset Management LLC bought a new position in Cullinan Therapeutics in the 1st quarter worth about $618,000. Creative Planning increased its stake in shares of Cullinan Therapeutics by 222.2% during the second quarter. Creative Planning now owns 41,723 shares of the company’s stock valued at $314,000 after buying an additional 28,773 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Cullinan Therapeutics by 122.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 97,069 shares of the company’s stock worth $731,000 after purchasing an additional 53,522 shares during the period. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics News Summary

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: In the Phase 3 REZILIENT3 trial, first-line zipalertinib combined with chemotherapy delivered a six-month improvement in median progression-free survival versus chemotherapy alone in patients with EGFR exon 20 insertion-positive non-small cell lung cancer. The result strengthens the potential commercial value of Cullinan’s lead drug and supports its regulatory strategy. REZILIENT3 Phase 3 trial results
• Neutral Sentiment: Cullinan hosted a virtual analyst and investor event to discuss the interim REZILIENT3 data presented at the IASLC 2026 World Conference on Lung Cancer. Management participation provides investors with additional detail on the efficacy, safety profile, and development path for zipalertinib. Cullinan investor event announcement
• Neutral Sentiment: The shareholder and analyst call transcript may clarify how management views the interim findings, remaining regulatory requirements, and the broader outlook for zipalertinib. Investors are likely focused on whether the results can support approval and meaningful adoption in a competitive lung-cancer market. Cullinan shareholder and analyst call transcript
• Negative Sentiment: Despite the six-month progression-free-survival benefit, reports indicated that CGEM shares fell as investors assessed the full trial package. The negative reaction implies concerns about the interim nature of the data, the magnitude of the benefit relative to expectations, or uncertainty around regulatory and commercial execution.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.